Remarkably, in two cases,both METTL3 and FTO or ALBKBH5 inhibitors resulted effective anticanceragents even in the same AML cell line.152−154 Consequently, the disruptionof METTL3–METTL14 activity may potentially contribute to theimpairment of essential physiological processes, thereby leading todetrimental outcomes. The gene discussed is FTO; the disease is acute myeloid leukemia.